Investigational drug · Phase 2
AL-001
Also called: lithium salicylate, L-proline cocrystal
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Wet Age-related Macular Degeneration (wAMD), Bipolar I Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
11
Any phase or sponsor naming "AL-001"
First trial start
2023
Sep 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AL-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Wet Age-related Macular Degeneration (wAMD)
- Bipolar I Disorder
Approved drugs for the same conditions: Bipolar disorder · Wet macular degeneration · Psychiatry · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "AL-001" as an intervention, largest first.
- A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)Pivotal-lookingTerminated
Alector Inc.Industry
NCT04374136 · 119 participants · Start Jul 23, 2020 · Primary completion Sep 1, 2025
Drug: Part 1 Blinded - AL001; Part 1 Blinded - Placebo and 2 more · For: Frontotemporal Dementia
Sites: Phoenix, Arizona; La Jolla, California; Aurora, Colorado · 44 sites in all
Alzamend Neuro, Inc.Industry
NCT05363293 · 65 participants · Start May 4, 2022 · Primary completion Apr 14, 2023
Drug: AL001 · For: Alzheimer's Disease; Healthy Non-elderly and Elderly Adults
Sites: Decatur, Georgia; Mount Royal, Canada
Alector Inc.Industry
NCT03636204 · 64 participants · Start Sep 14, 2018 · Primary completion Dec 31, 2019
Drug: AL001 · For: Healthy; Frontotemporal Dementia
Sites: Birmingham, Alabama; San Francisco, California; Orlando, Florida · 8 sites in all
- Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDNot yet recruiting
Beijing Anlong Biopharmaceutical Co., Ltd.Industry
NCT06839339 · 40 participants (planned) · Start Feb 18, 2025 · Primary completion Sep 30, 2026
Drug: AL-001; Aflibercept · For: Wet Age-related Macular Degeneration (wAMD)
Sites: Beijing, China
Zhongnan HospitalAcademic, hospital or other
NCT05817214 · 35 participants (planned) · Start Feb 16, 2023 · Primary completion Nov 30, 2025
Drug: Cadonilimab; Anlotinib and 1 more · For: Cervical Cancer
Sites: Wuhan, China
Alector Inc.Industry
NCT03987295 · 33 participants · Start Sep 27, 2019 · Primary completion Jun 5, 2024
Drug: AL001 · For: Frontotemporal Dementia
Sites: San Francisco, California; Rochester, Minnesota; Philadelphia, Pennsylvania · 12 sites in all
- Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMDActive, not recruiting
Beijing Anlong Biopharmaceutical Co., Ltd.Industry
NCT06707753 · 21 participants (planned) · Start Sep 11, 2023 · Primary completion Aug 31, 2025
Drug: AL-001 · For: Wet Age-related Macular Degeneration (wAMD)
Sites: Beijing, China
Alzamend Neuro, Inc.Industry
NCT07540338 · 20 participants (planned) · Start May 11, 2026 · Primary completion Jul 2027
Drug: AL001; Lithium carbonate · For: Bipolar I Disorder
Sites: Boston, Massachusetts
- Continuation Study for LatozinemabPivotal-lookingTerminated
Alector Inc.Industry
NCT06111014 · 17 participants · Start Dec 8, 2023 · Primary completion Sep 1, 2025
Drug: Latozinemab · For: Neurodegenerative Diseases
Sites: Phoenix, Arizona; Rochester, Minnesota; New York, New York · 18 sites in all
Alzamend Neuro, Inc.Industry
NCT06921590 · 15 participants · Start May 9, 2025 · Primary completion Dec 15, 2025
Drug: AL001; Lithium Carbonate Capsule · For: Pharmacokinetics; Neurology
Sites: Boston, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration.
Liu X, Liu H, Wang L, et al. · Front Genet 2026
- In Situ Interface Reaction Enables Efficient Deep-Blue Perovskite Light-Emitting Diodes.
Cao LX, Shen Y, Zhang K, et al. · Angew Chem Int Ed Engl 2025
- Recycling primary lithium batteries using a coordination chemistry approach: recovery of lithium and manganese residues in the form of industrially important materials.
Petrus R, Kowaliski A, Lis T · Dalton Trans 2024
- Catalysis by subsurface metal atoms in Al(001) through electron transfer.
Sun B, Ma D · Natl Sci Rev 2024
- Experimental, Grand canonical Monte Carlo, and Density Functional Theory studies for comparing halloysite and kaolinite on heavy metals fate during pyrolysis of solid waste.
He T, Zhang M, Jin B · Sci Total Environ 2023
- Influence of pH on Ice Nucleation by Kaolinite: Experiments and Molecular Simulations.
Ren Y, Bertram AK, Patey GN · J Phys Chem A 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.